AbbVie Inc (ABBV)vsEmpro Group Inc. Ordinary shares (EMPG)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
EMPG
Empro Group Inc. Ordinary shares
$17.36
0.00%
HEALTHCARE · Cap: $143.05M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1173820% more annual revenue ($64.39B vs $5.48M). EMPG leads profitability with a 13.7% profit margin vs 9.8%. ABBV trades at a lower P/E of 72.0x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
EMPG
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Intrinsic value data unavailable for EMPG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Every $100 of equity generates 49 in profit
Strong operational efficiency at 36.1%
Revenue surging 141.6% year-over-year
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 17.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : EMPG
The strongest argument for EMPG centers on Return on Equity, Operating Margin, Revenue Growth. Revenue growth of 141.6% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : EMPG
The primary concerns for EMPG are Price/Book, EPS Growth, Market Cap. A P/E of 192.9x leaves little room for execution misses.
Key Dynamics to Monitor
ABBV profiles as a value stock while EMPG is a growth play — different risk/reward profiles.
EMPG is growing revenue faster at 141.6% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 47/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Empro Group Inc. Ordinary shares
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Empro Group Inc., through its subsidiary, sells healthcare and beauty products in Malaysia and internationally. The company is headquartered in Shah Alam, Malaysia.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?